Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 412 | 62 | 341 |
| Samples | 220 | 40 | 175 |
| Peptides | 165 | 34 | 136 |
Function
ANGPTL4 · Angiopoietin like 4
This gene encodes a glycosylated, secreted protein containing a C-terminal fibrinogen domain. The encoded protein is induced by peroxisome proliferation activators and functions as a serum hormone that regulates glucose homeostasis, lipid metabolism, and insulin sensitivity. This protein can also act as an apoptosis survival factor for vascular endothelial cells and can prevent metastasis by inhibiting vascular growth and tumor cell invasion. The C-terminal domain may be proteolytically-cleaved from the full-length secreted protein. Decreased expression of this gene has been associated with type 2 diabetes. Alternative splicing results in multiple transcript variants. This gene was previously referred to as ANGPTL2 but has been renamed ANGPTL4. [provided by RefSeq, Sep 2013].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 150 amino-acid changes on canonical ENST00000301455 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ANGPTL4 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ANGPTL4 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Rhabdomyosarcoma | 0/33 0% | 9/171 5% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Hodgkins Lymphoma | 2/16 12% | 1/122 1% |
| Melanoma | 1/210 0% | 23/1899 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Endometrial Carcinoma | 0/42 0% | 7/612 1% |
| Thyroid Gland Carcinoma | 1/45 2% | 15/1592 1% |
| Osteosarcoma | 2/45 4% | 0/166 0% |
| Ewings Sarcoma | 2/63 3% | 1/262 0% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Colorectal Carcinoma | 5/143 4% | 23/3239 1% |
| Non-Small Cell Lung Carcinoma | 8/304 3% | 5/1390 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Bladder Carcinoma | 0/58 0% | 7/956 1% |
| Other Sarcomas | 2/69 3% | 3/699 0% |
| Gastric Carcinoma | 1/74 1% | 10/1809 1% |
| Other Solid Cancers | 2/94 2% | 7/1515 0% |
| Ovarian Carcinoma | 3/109 3% | 3/998 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 13/2550 1% |
| Biliary Tract Carcinoma | 1/54 2% | 4/950 0% |
| Meningioma | 0/3 0% | 1/252 0% |
| Head and Neck Carcinoma | 0/85 0% | 6/1574 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 3/810 0% |
| Non-Cancerous | 0/104 0% | 3/830 0% |
| Breast Carcinoma | 2/144 1% | 8/3264 0% |
| Glioma | 0/52 0% | 5/2127 0% |
| Neuroblastoma | 0/87 0% | 3/1331 0% |
| Hepatocellular Carcinoma | 0/46 0% | 4/2210 0% |
| Other Blood Cancers | 0/61 0% | 5/2725 0% |
Mutation Distribution
Where ANGPTL4 is mutated · all tissues, split by cell line vs tissue
How many mutations in ANGPTL4 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 412 mutations in ANGPTL4
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|